Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 11/27/25
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous UrticariaZacks Investment Research • 11/25/25
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)GlobeNewsWire • 11/25/25
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticariaGlobeNewsWire • 11/25/25
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision LossBenzinga • 11/20/25
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HDZacks Investment Research • 11/20/25
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved IndicationsGlobeNewsWire • 11/19/25
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and RadiationGlobeNewsWire • 11/19/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/17/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha • 11/17/25
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria ProgramsGlobeNewsWire • 11/13/25
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline TranscriptSeeking Alpha • 11/10/25
Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority reviewGlobeNewsWire • 11/07/25
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product AwardGlobeNewsWire • 10/31/25
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven ComebackSeeking Alpha • 10/29/25
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/28/25
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea WeaknessBenzinga • 10/28/25